Jian Ming1, Yabing Zhang2, Xun Xu3, Mingwei Zhao4, Yusheng Wang5, Youxin Chen6, Feng Zhang7, Jiawei Wang7, Jun Liu1, Xinran Zhao1, Rong Han8, Shanlian Hu9. 1. Real-World Solutions, IQVIA China, Shanghai 200041, China. 2. Humanities College, Shanghai Institute of Technology, Shanghai 201418, China. 3. Shanghai General Hospital, Shanghai 200080, China. 4. Peking University People's Hospital, Beijing 100044, China. 5. Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. 6. Peking Union Medical College Hospital, Beijing 100005, China. 7. Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China. 8. Medical Affairs, Pharmaceuticals, Bayer Healthcare Company Ltd., Beijing 100020, China. 9. School of Public Health, Fudan University, Shanghai 200040, China.
Abstract
Aim: To evaluate the cost-effectiveness of intravitreal aflibercept compared with macular laser photocoagulation and ranibizumab for diabetic macular edema (DME) in China. Methods: A Markov model was developed to reflect the vision changes in DME patients. Parameters were estimated from VIVID-EAST trial data, published literature and physician surveys. Results: In a 20-year horizon, intravitreal aflibercept was associated with 7.825 quality-adjusted life years (QALYs) and 217,841 Chinese Yuan Renminbi (CNY), laser photocoagulation was associated with 7.189 QALYs and 135,489 CNY, and ranibizumab was associated with 7.462 QALYs and 222,477 CNY. The incremental cost-effectiveness ratios were 129,397 CNY/QALY and -12,774 CNY/QALY for intravitreal aflibercept versus laser photocoagulation and ranibizumab, respectively. Conclusion: Intravitreal aflibercept was considered as a cost-effective strategy for DME when compared with laser photocoagulation; it was considered as a dominant strategy when compared with ranibizumab.
Aim: To evaluate the cost-effectiveness of intravitreal aflibercept compared with macular laser photocoagulation and ranibizumab for diabetic macular edema (DME) in China. Methods: A Markov model was developed to reflect the vision changes in DMEpatients. Parameters were estimated from VIVID-EAST trial data, published literature and physician surveys. Results: In a 20-year horizon, intravitreal aflibercept was associated with 7.825 quality-adjusted life years (QALYs) and 217,841 Chinese Yuan Renminbi (CNY), laser photocoagulation was associated with 7.189 QALYs and 135,489 CNY, and ranibizumab was associated with 7.462 QALYs and 222,477 CNY. The incremental cost-effectiveness ratios were 129,397 CNY/QALY and -12,774 CNY/QALY for intravitreal aflibercept versus laser photocoagulation and ranibizumab, respectively. Conclusion: Intravitreal aflibercept was considered as a cost-effective strategy for DME when compared with laser photocoagulation; it was considered as a dominant strategy when compared with ranibizumab.